Amphotericin B lipid complex: In visceral leishmaniasis

Drugs

Volumn 64, Issue 17, 2004, Pages 1905-1911

  Goldsmith, David R ^a   Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; MEGLUMINE ANTIMONATE;

CHILL; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DRUG UPTAKE; EUROPE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEISHMANIA; MACROPHAGE; NEPHROTOXICITY; NONHUMAN; REVIEW; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS; VOMITING;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CLINICAL TRIALS; DRUG COMBINATIONS; HALF-LIFE; HUMANS; LEISHMANIASIS, VISCERAL; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLGLYCEROLS;

HUMAN IMMUNODEFICIENCY VIRUS; PROTOZOA;

EID: 4544262736     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464170-00004     Document Type: Review

References (22)

1. Davidson RN. Practical guide for the treatment of leishmaniasis. Drugs 1998 Dec; 56 (6): 1009-18
2. Murray HW. Clinical and experimental advances in treatment of visceral leishmaniasis. Antimicrob Agents Chemother 2001 Aug; 45 (8): 2185-97
3. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997 Apr; 24 (4): 684-703
4. Davidson RN. AIDS and leishmaniasis. Genitourin Med 1997; 73: 237-9
5. Herwaldt BL. Leishmaniasis. Lancet 1999 Oct; 354 (9185): 1191-9
6. Elan Pharmaceuticals Europe. Abelcet: amphotericin B lipid complex: product monograph. 3rd ed. Cheshire: Gardiner-Caldwell Communications, 2000
7. Brajtburg J, Bolard J. Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev 1996 Oct; 9 (4): 512-31
8. Larabi M, Yardley V, Loiseau PM, et al. Toxicity and antileishmanial activity of a new stable lipid suspension of amphotericin B. Antimicrob Agents Chemother 2003 Dec; 47 (12): 3774-9
9. Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int J Antimicrob Agents 2000 Feb; 13 (4): 243-8
10. Piñero JE, Martinez S, del Castillo A, et al. In vitro susceptibility of Leishmania infantum strains isolated from Spanish HIV-positive patients to Abelcet and Fungizone [letter]. J Antimicrob Chemother 2002 Aug; 50 (2): 304-6
11. Gangneux JP, Sulahian A, Garin YJ-F, et al. Lipid formulations of amphotericin B in the treatment of experimental visceral leishmaniasis due to Leishmania infantum. Trans R Soc Trop Med Hyg 1996 Sep-Oct; 90 (5): 574-7
12. Mullen AB, Carter KC, Baillie AJ. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob Agents Chemother 1997 Oct; 41 (10): 2089-92
13. Adedoyin A, Bernardo JF, Swenson CE, et al. Pharmacokinetic profile of Abelcet (amphotericin B lipid complex injection): combined experience from phase I and phase II studies. Antimicrob Agents Chemother 1997 Oct; 41 (10): 2201-8
14. Adedoyin A, Swenson CE, Bolcsak LE, et al. A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections. Antimicrob Agents Chemother 2000 Oct; 44 (10): 2900-2
15. Sundar S, Mehta H, Suresh AV, et al. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004 Feb; 38 (3): 377-83
16. Sundar S, Agrawal NK, Sinha PR, et al. Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med 1997 Jul; 127 (2): 133-7
17. Sundar S, Goyal AK, Mandai AK, et al. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis. J Assoc Physicians India 1999 Feb; 47 (2): 186-8
18. Sundar S, Goyal AK, More DK, et al. Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex. Ann Trop Med Parasitol 1998 Oct; 92 (7): 755-64
19. Laguna F, Videla S, Jiménez-Mejías ME, et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother 2003 Sep; 52 (3): 464-8
20. López-Vélez R, Videla S. Márquez M, et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2004 Mar; 53 (3): 540-3
21. Elan Pharma Ltd. Abelcet: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2004 Mar 15]
22. Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003 May; 25 (5): 1295-320